

Jeffrey N Myers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9463649/publications.pdf>

Version: 2024-02-01

123
papers

8,165
citations

87888

38
h-index

49909

87
g-index

124
all docs

124
docs citations

124
times ranked

12523
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	12.6	1,568
2	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6582-6592.	7.0	493
3	Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers. <i>Cancer Discovery</i> , 2013, 3, 770-781.	9.4	484
4	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	12.4	372
5	Extracapsular spread. <i>Cancer</i> , 2001, 92, 3030-3036.	4.1	308
6	Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 744-751.	1.6	271
7	<i>TP53</i> Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence. <i>Clinical Cancer Research</i> , 2012, 18, 290-300.	7.0	254
8	Loss of p53 drives neuron reprogramming in head and neck cancer. <i>Nature</i> , 2020, 578, 449-454.	27.8	241
9	<i>TP53</i> Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2682-2692.	2.6	233
10	Squamous cell carcinoma of the tongue in young adults: Increasing incidence and factors that predict treatment outcomes. <i>Otolaryngology - Head and Neck Surgery</i> , 2000, 122, 44-51.	1.9	226
11	Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. <i>Molecular Cell</i> , 2014, 54, 960-974.	9.7	196
12	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017, 31, 225-239.	16.8	190
13	Evolutionary Action Score of <i>TP53</i> Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. <i>Cancer Research</i> , 2015, 75, 1527-1536.	0.9	139
14	An orthotopic nude mouse model of oral tongue squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2002, 8, 293-8.	7.0	128
15	Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. <i>Nature Communications</i> , 2016, 7, 12601.	12.8	123
16	Key tumor suppressor genes inactivated by CpG greater promoter methylation and somatic mutations in head and neck cancer. <i>Epigenetics</i> , 2014, 9, 1031-1046.	2.7	122
17	Erlotinib and the Risk of Oral Cancer. <i>JAMA Oncology</i> , 2016, 2, 209.	7.1	111
18	Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk <i>TP53</i> Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 608-619.	4.1	97

#	ARTICLE	IF	CITATIONS
19	Sentinel Lymph Node Biopsy Revisited: Ultrasound-Guided Photoacoustic Detection of Micrometastases Using Molecularly Targeted Plasmonic Nanosensors. <i>Cancer Research</i> , 2014, 74, 5397-5408.	0.9	92
20	Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	7.0	91
21	Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. <i>Oral Oncology</i> , 2018, 87, 49-57.	1.5	91
22	Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. <i>Cancer Research</i> , 2021, 81, 1431-1440.	0.9	84
23	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 5650-5662.	7.0	83
24	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015, 75, 1205-1215.	0.9	78
25	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	4.1	72
26	Variations in HPV function are associated with survival in squamous cell carcinoma. <i>JCI Insight</i> , 2019, 4, .	5.0	67
27	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4643-4650.	7.0	64
28	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020, 26, 3211-3219.	7.0	64
29	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021, 27, 4557-4565.	7.0	61
30	New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. <i>Cancer Prevention Research</i> , 2015, 8, 1027-1035.	1.5	60
31	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	1.5	53
32	Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 18707-18714.	1.8	52
33	JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 6.	8.6	51
34	Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. <i>Oncotarget</i> , 2017, 8, 86369-86383.	1.8	50
35	Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 74, 8-14.	1.5	46
36	Melanoma of the Head and Neck: Current Concepts in Diagnosis and Management. <i>Laryngoscope</i> , 2001, 111, 1209-1222.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCL-1 and XIAP Antiapoptotic Proteins. <i>Clinical Cancer Research</i> , 2015, 21, 4831-4844.	7.0	45
38	Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. <i>Oncogene</i> , 2018, 37, 1279-1292.	5.9	43
39	Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 128.	2.2	42
40	Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 1131-1137.	2.0	40
41	Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1194-1201.	2.0	38
42	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. <i>Cancer Research</i> , 2018, 78, 781-797.	0.9	37
43	Sentinel lymph node biopsy for ocular adnexal melanoma. <i>Acta Ophthalmologica</i> , 2017, 95, e323-e328.	1.1	36
44	High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1727-1733.	7.0	36
45	Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. <i>Head and Neck</i> , 2020, 42, 1179-1186.	2.0	34
46	Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress. <i>Cancers</i> , 2020, 12, 1670.	3.7	33
47	Matrix Metalloproteinases in Head and Neck Carcinoma—Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 612-618.	1.9	30
48	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. <i>International Journal of Radiation Biology</i> , 2021, 97, 1121-1128.	1.8	30
49	The p53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e104821.	2.5	29
50	The impact of intraoperative opioid use on survival after oral cancer surgery. <i>Oral Oncology</i> , 2017, 74, 1-7.	1.5	29
51	Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2021, 29, 2305-2317.	2.2	29
52	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 72, 90-97.	1.5	28
53	Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. <i>JCI Insight</i> , 2020, 5, .	5.0	28
54	Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53R172H. <i>Journal of Pathology</i> , 2016, 240, 224-234.	4.5	27

#	ARTICLE	IF	CITATIONS
55	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk <i>TP53</i> Mutation. <i>Clinical Cancer Research</i> , 2017, 23, 6541-6554.	7.0	27
56	The mutational landscape of early and typical onset oral tongue squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 544-553.	4.1	27
57	Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 673-677.	1.9	25
58	Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. <i>Cancer Letters</i> , 2018, 431, 64-72.	7.2	25
59	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. <i>Head and Neck</i> , 2017, 39, 708-715.	2.0	24
60	Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model. <i>Clinical Cancer Research</i> , 2008, 14, 5081-5089.	7.0	23
61	Proton versus photon radiation-induced cell death in head and neck cancer cells. <i>Head and Neck</i> , 2019, 41, 46-55.	2.0	23
62	STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e81819.	2.5	22
63	Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. <i>Cancer Letters</i> , 2017, 392, 71-82.	7.2	22
64	Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018, 124, 84-94.	4.1	22
65	Targeted Molecular Therapy for Oral Cancer With Epidermal Growth Factor Receptor Blockade. <i>JAMA Otolaryngology</i> , 2002, 128, 875.	1.2	21
66	Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. <i>International Journal of Cancer</i> , 2017, 140, 1571-1580.	5.1	21
67	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 439-447.	2.0	20
68	Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.		20
69	Proton and photon radiosensitization effects of niraparib, a PARP1/2 inhibitor, on human head and neck cancer cells. <i>Head and Neck</i> , 2020, 42, 2244-2256.	2.0	20
70	Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy. <i>Head and Neck</i> , 2015, 37, 1116-1121.	2.0	19
71	Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2901-2908.	4.1	17
72	Persistent and Chronic Postoperative Opioid Use in a Cohort of Patients with Oral Tongue Squamous Cell Carcinoma. <i>Pain Medicine</i> , 2020, 21, 1061-1067.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	1.5	17
74	Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6008-6008.	1.6	17
75	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , 2021, 12, 6340.	12.8	17
76	Sentinel Lymph Node Biopsy Provides Prognostic Value in Thick Head and Neck Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 372-378.	1.9	16
77	Downregulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence. <i>Head and Neck</i> , 2016, 38, E934-40.	2.0	16
78	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. <i>Head and Neck</i> , 2017, 39, 633-638.	2.0	16
79	Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 758.	2.6	16
80	Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma. <i>Oral Oncology</i> , 2019, 97, 56-61.	1.5	16
81	Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1257-1269.	4.1	15
82	Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. <i>Head and Neck</i> , 2016, 38, E1926-34.	2.0	14
83	The effects of zinc on radiation-induced dysgeusia: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2020, 28, 1-12.	2.2	13
84	Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. <i>Cancer Prevention Research</i> , 2021, 14, 767-778.	1.5	13
85	Reconstruction of intraoral oncologic surgical defects with Integra [®] bilayer wound matrix. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 213-219.	0.5	12
86	Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. <i>Translational Oncology</i> , 2018, 11, 477-486.	3.7	11
87	Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients. <i>International Journal of Biological Sciences</i> , 2019, 15, 1336-1344.	6.4	11
88	Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. <i>Head and Neck</i> , 2019, 41, 2688-2695.	2.0	11
89	Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. <i>Head and Neck</i> , 2020, 42, 289-301.	2.0	11
90	Association between postoperative complications and long-term oncologic outcomes following total laryngectomy: 10-year experience at MD Anderson Cancer Center. <i>Cancer</i> , 2020, 126, 4905-4916.	4.1	10

#	ARTICLE	IF	CITATIONS
91	Interrupting Neuron-Tumor Interactions to Overcome Treatment Resistance. <i>Cancers</i> , 2020, 12, 3741.	3.7	10
92	Characterizing distant metastases and survival in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 2101-2109.	2.0	10
93	The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2021, 8, 3-13.	1.8	10
94	Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. <i>Life Sciences</i> , 2021, 278, 119541.	4.3	9
95	Metabolic interrogation as a tool to optimize chemotherapeutic regimens. <i>Oncotarget</i> , 2017, 8, 18154-18165.	1.8	8
96	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-effects model analysis of a prospective observational cohort registry. <i>Cancer</i> , 2021, 127, 2453-2464.	4.1	7
97	Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 4413-4420.	4.1	7
98	Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 4498-4510.	4.1	6
99	Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2021, 127, 1238-1245.	4.1	6
100	Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. <i>Cancers</i> , 2021, 13, 1471.	3.7	6
101	Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 196-207.	1.4	6
102	Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. <i>Otolaryngology</i> , 2017, 5, 24.		5
103	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. <i>Journal of Cutaneous Pathology</i> , 2018, 46, 152-158.	1.3	5
104	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 266-277.	6.3	5
105	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. <i>Cancer</i> , 2021, 127, 2916-2925.	4.1	5
106	Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963441.	0.7	4
107	Desmoplastic Melanoma of the Periorbital Region. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e48-e52.	0.8	4
108	PI3K-kinase pathway biomarkers in oral cancer and tumor immune cells. <i>Head and Neck</i> , 2018, 41, 615-622.	2.0	4

#	ARTICLE	IF	CITATIONS
109	IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. <i>Oncotarget</i> , 2016, 7, 77138-77151.	1.8	4
110	Outcomes of microvascular flap reconstruction of the head and neck in patients receiving systemic immunosuppressive therapy for organ transplantation. <i>Journal of Surgical Oncology</i> , 2018, 117, 1575-1583.	1.7	3
111	Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , 2020, 42, 3396-3404.	2.0	3
112	Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021, 144, 169-177.	2.8	3
113	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. <i>Clinical Cancer Research</i> , 2022, , .	7.0	3
114	Adjuvant Immunotherapy for patients with melanoma. , 1998, 20, 270-270.		2
115	Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 14-23.	1.3	2
116	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. <i>Head and Neck</i> , 2021, 43, 1592-1603.	2.0	2
117	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6010-6010.	1.6	2
118	Extracapsular spread. , 2001, 92, 3030.		1
119	Targeting TP53 to augment therapeutic response in head and neck cancer. , 2020, , 65-88.		1
120	Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9519-9519.	1.6	1
121	A Tale of Two Cancers: Carcinomas of the Oral Cavity and Oropharynx. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, xiii-xvi.	1.1	0
122	Neural reprogramming via microRNAs: the new kid on the p53-deficient block. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1756723.	0.7	0
123	Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6067-6067.	1.6	0